Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Public ClinicalTrials.gov record NCT02684058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high grade glioma (HGG)
Study identification
- NCT ID
- NCT02684058
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 151 participants
Conditions and interventions
Conditions
- Diffuse Astrocytoma
- Anaplastic Astrocytoma
- Astrocytoma
- Oligodendroglioma, Childhood
- Anaplastic Oligodendroglioma
- Glioblastoma
- Pilocytic Astrocytoma
- Giant Cell Astrocytoma
- Pleomorphic Xanthoastrocytoma
- Anaplastic Pleomorphic Xanthoastrocytoma
- Angiocentric Glioma
- Chordoid Glioma of Third Ventricle
- Gangliocytoma
- Ganglioglioma
- Anaplastic Ganglioglioma
- Dysplastic Gangliocytoma of Cerebrellum
- Desmoplastic Infantile Astrocytoma and Ganglioglioma
- Papillary Glioneuronal Tumor
- Rosette-forming Glioneurona Tumor
- Central Neurocytoma
- Extraventricular Neurocytoma
- Cerebellar Iponeurocytoma
Eligibility (public fields only)
- Age range
- 12 Months to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 27, 2017
- Primary completion
- Aug 22, 2021
- Completion
- Apr 27, 2023
- Last update posted
- Dec 12, 2023
2017 – 2023
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital of Orange County | Orange | California | 92868 | — |
| Childrens National Hospital | Washington D.C. | District of Columbia | 20010 | — |
| Nicklaus Childrens Hospital | Miami | Florida | 33155 | — |
| Ann and Robert H Lurie Childrens Hospital of Chicago . | Chicago | Illinois | 60611 | — |
| Indiana University School of Medicine . | Indianapolis | Indiana | 46202-2810 | — |
| Johns Hopkins University IDS Pharmacy John Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Washington University School of Medicine SC | St Louis | Missouri | 63110 | — |
| Cincinnati Childrens Hospital Medical Center Cancer & Blood Disease Inst. | Cincinnati | Ohio | 45229-3039 | — |
| St Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| Texas Children s Hospital Baylor College of Medicine | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02684058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02684058 live on ClinicalTrials.gov.